TNGX Past Earnings

— Presenting past earnings and revenue for Tango Therapeutics (TNGX) from Q3 2021 to Q4 2025, based on our latest update on 5/6/2026. The past earnings numbers are per-share values while the revenue is the grand total for the quarter. Studying these TNGX past earnings numbers both in chart format and in tables can help investors visualize any typical seasonality patterns, as well as determine whether the company has grown over time.

TNGX Past Earnings Q&A

On this page we presented the TNGX past earnings date information for Tango Therapeutics. Reviewing that TNGX Past Earnings for the company, we see that the highest past earnings result in our data set was in Q3 2025, when TNGX posted gaap of 0.140/share. Meanwhile the lowest TNGX past earnings result was in Q1 2025, when TNGX posted gaap of -0.360/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2025 when TNGX reported 0.05B in revenue, while the smallest revenue quarter was Q4 2025 when TNGX reported NA in revenue.

Any self directed investor doing their due diligence on TNGX or any other given stock can benefit from researching all of the Tango Therapeutics past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Tango Therapeutics past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for TNGX. Thanks for visiting, and the next time you need to research TNGX past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.